Pharming Short Term Debt from 2010 to 2024

PHAR Stock  USD 7.65  0.12  1.59%   
Pharming Group Short Term Debt yearly trend continues to be relatively stable with very little volatility. Short Term Debt is likely to drop to about 5.2 M. During the period from 2010 to 2024, Pharming Group Short Term Debt destribution of quarterly values had range of 53.2 M from its regression line and mean deviation of  13,413,441. View All Fundamentals
 
Short Term Debt  
First Reported
2009-12-31
Previous Quarter
M
Current Value
7.2 M
Quarterly Volatility
23.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 16.7 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 6.5 M, as well as many indicators such as Price To Sales Ratio of 2.62, Dividend Yield of 0.0 or PTB Ratio of 3.07. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
Check out the analysis of Pharming Group Correlation against competitors.

Latest Pharming Group's Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Pharming Group NV over the last few years. It is Pharming Group's Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Pretty Stable
   Short Term Debt   
       Timeline  

Pharming Short Term Debt Regression Statistics

Arithmetic Mean11,920,304
Geometric Mean3,895,218
Coefficient Of Variation141.07
Mean Deviation13,413,441
Median4,002,000
Standard Deviation16,816,003
Sample Variance282.8T
Range53.2M
R-Value0.20
Mean Square Error292.8T
R-Squared0.04
Significance0.48
Slope737,369
Total Sum of Squares3958.9T

Pharming Short Term Debt History

20245.2 M
20235.4 M
20225.2 M
20212.4 M
2020M
201953.2 M
201840.6 M

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as Short Term Debt, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Short Term Debt5.4 M5.2 M

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.